IO Biotech reports Q1 net loss of $17.0M; Phase 3 melanoma trial on track for mid-2023 enrollment milestone

IO Biotech, Inc.

2023-Q1 EPS reported -$0.59

Net loss $17.0M for Q1 2023, nearly flat vs $17.2M in Q1 2022.
Cash and equivalents $128.5M as of March 31, 2023; expected to fund operations through Q3 2024.
Phase 3 pivotal trial (IOB-013) in advanced melanoma: expects 225 patients randomized by mid-2023, full enrollment by end of 2023.
Phase 2 basket trial (IOB-022) in lung cancer: 4 partial responses, 4 stable disease among 9 evaluable patients; safety consistent.
FDA cleared IND for IO102-IO103 in neo-adjuvant/adjuvant solid tumors; Phase 2 trial to start H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IO Biotech, Inc. reported the first quarter ended March 31, 2023 results: net income Net loss for the three months ended March 31, 2023 was $17.0 million.

Period: the first quarter ended March 31, 2023
Net income: Net loss for the three months ended March 31, 2023 was $17.0 million
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2023 was $17.0 million, compared to $17.2 million for the three months ended March 31, 2022.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

IO Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-142000

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.